Aimmune’s peanut allergy med moves toward EU approval
CHMP grants Palforzia a positive opinion for the treatment of peanut allergic patients
Read Moreby Lucy Parsons | Oct 20, 2020 | News | 0
CHMP grants Palforzia a positive opinion for the treatment of peanut allergic patients
Read Moreby Anna Smith | Mar 27, 2019 | News | 0
Aimmune to file peanut allergy drug in Europe based on Phase III data showing an improvement in peanut tolerance.
Read Moreby Selina McKee | Feb 21, 2018 | News | 0
A Phase III trial assessing Aimmune Therapeutics’ experimental peanut allergy drug AR101 has hit its primary targets.
Read Moreby Selina McKee | Oct 17, 2017 | News | 0
Sanofi and Regeneron have unveiled positive results from a mid-stage study exploring the potential of the biologic dupilumab in adults with eosinophilic esophagitis, and also signed a deal with Aimmune Therapeutics to test an experimental peanut allergy therapy.
Read Moreby Selina McKee | Jul 12, 2017 | News | 0
Children and adolescents in the UK with peanut allergy are among the first to enrol in a Europe-wide study investigating a new oral immunotherapy for the condition.
Read More





PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
